BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 07, 2008
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 4/4 cls
deCode (NASDAQ:DCGN) Jefferies Robin Campbell Price target Hold -7% $1.45
Campbell lowered his ADR target to $1.70 from $4 as worldwide credit markets continued tightening. The company said in early March that it had written down $7.8M of auction rate securities (ARS) and Campbell is concerned the company may not have more than 12 months of cash. He fears deCode may not be able to liquidate the additional $24.8M in ARSs. Campbell did raise his FY08 and FY09 revenue estimates to $33.6M from $21.8M and to $35.4M from $26.5 million. The company has launched at least three diagnostic tests in the past 12 months.
Dyax (NASDAQ:DYAX) Leerink John Sullivan Discontinued NA 4% $4.98
The firm dropped coverage of the antibody, cardiovascular and pulmonary company because it no longer views it as "strategic" for its life science tools coverage.
Elan (NYSE:ELN) Stanford Group Han Li New Hold 7% $21.67
Li believes there is upside potential for bapineuzumab (AAB-001), a humanized monoclonal...

Read the full 1013 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >